Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

被引:0
|
作者
Dong, Wen [1 ]
Lei, Pengfei [2 ]
Liu, Xin [3 ]
Li, Qin [3 ]
Cheng, Xiangyang [4 ]
机构
[1] Hainan Canc Hosp, Dept Resp Med, Haikou, Hainan, Peoples R China
[2] Yueyang Second Peoples Hosp, Dept Cardiothorac Surg, Yueyang, Peoples R China
[3] Geneplus Beijing Inst, Dept Med Ctr, Beijing, Peoples R China
[4] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
lung cancer; EML4-ALK; nivolumab; complete remission; PD-L1; ALK; MUTATIONS; OUTCOMES; PATHWAY; CANCER; EGFR;
D O I
10.3389/fimmu.2021.686057
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement.
引用
收藏
页数:5
相关论文
共 28 条
  • [21] The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression
    Siyuan Dong
    Xiaohan Qu
    Wenya Li
    Xinwen Zhong
    Peiwen Li
    Shize Yang
    Xitao Chen
    Mingrui Shao
    Lin Zhang
    Journal of Hematology & Oncology, 8
  • [22] ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
    Popat, S.
    Tiseo, M.
    Gettinger, S.
    Peters, S.
    Haney, J.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer
    Xu, Xinyan
    Liu, Di
    Wen, Junmiao
    Chen, Jiayan
    Fan, Min
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2500 - 2507
  • [24] A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer
    Peng, Jie
    Xiao, Lushan
    Zou, Dan
    Han, Lijie
    FRONTIERS IN MEDICINE, 2022, 9
  • [25] Design of ALTA-1 L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)positive non-small cell lung cancer (NSCLC).
    Tiseo, Marcello
    Popat, Sanjay
    Gettinger, Scott N.
    Peters, Solange
    Haney, Jeff
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report
    Qiu, Dong
    Zhang, Yu
    Xue, Ying-bo
    Shen, Qi
    Li, Hang
    Huang, Ping
    Hu, Jian-jun
    Wang, Yong-sheng
    THORACIC CANCER, 2019, 10 (04) : 1023 - 1028
  • [27] Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report
    Urushibara, Masayasu
    Ishizaka, Kazuhiro
    Matsutani, Noriyuki
    Takahashi, Mikiko
    Nagata, Masakazu
    Okumura, Taisuke
    Matsumoto, Yuuki
    Tatsuoka, Shinichiro
    Nenohi, Tsunehiro
    Amemiya, Takumasa
    Shimizu, Yohei
    Shirakawa, Takeshi
    Kato, Daisuke
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [28] Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report
    Masayasu Urushibara
    Kazuhiro Ishizaka
    Noriyuki Matsutani
    Mikiko Takahashi
    Masakazu Nagata
    Taisuke Okumura
    Yuuki Matsumoto
    Shinichiro Tatsuoka
    Tsunehiro Nenohi
    Takumasa Amemiya
    Yohei Shimizu
    Takeshi Shirakawa
    Daisuke Kato
    World Journal of Surgical Oncology, 21